APP and Alzheimer disease: Our results proposed that miR-451a overexpression in the mPFC of APP/PS1 mice could alleviate the AD pathology of APP/PS1 mice by specifically targeting BACE1 to counteract the deleterious β-secretase metabolites of APP.